Epizyme Inc. (NASDAQ:EPZM) has received an average recommendation of “Buy” from the ten analysts that are covering the stock. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $22.00.

A number of analysts have recently issued reports on EPZM shares. Leerink Swann reissued an “outperform” rating on shares of Epizyme in a research note on Friday, October 7th. Cowen and Company reissued a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Mizuho restated a “buy” rating and set a $18.00 target price on shares of Epizyme in a research report on Monday, June 20th. Royal Bank Of Canada restated an “outperform” rating and set a $26.00 target price on shares of Epizyme in a research report on Monday, June 20th. Finally, JMP Securities restated a “buy” rating and set a $28.00 target price on shares of Epizyme in a research report on Thursday, June 23rd.

In related news, insider Robert A. Copeland sold 4,000 shares of the business’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $10.37, for a total value of $41,480.00. Following the completion of the sale, the insider now owns 35,538 shares of the company’s stock, valued at approximately $368,529.06. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 25.40% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. acquired a new stake in Epizyme during the first quarter worth about $14,544,000. BlackRock Fund Advisors raised its stake in Epizyme by 42.0% in the first quarter. BlackRock Fund Advisors now owns 1,698,516 shares of the biopharmaceutical company’s stock worth $20,586,000 after buying an additional 502,627 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Epizyme by 550.8% in the first quarter. JPMorgan Chase & Co. now owns 153,656 shares of the biopharmaceutical company’s stock worth $1,862,000 after buying an additional 130,044 shares during the last quarter. Spark Investment Management LLC raised its stake in Epizyme by 52.6% in the first quarter. Spark Investment Management LLC now owns 331,300 shares of the biopharmaceutical company’s stock worth $4,015,000 after buying an additional 114,200 shares during the last quarter. Finally, Primecap Management Co. CA raised its stake in Epizyme by 24.3% in the first quarter. Primecap Management Co. CA now owns 6,518,627 shares of the biopharmaceutical company’s stock worth $79,006,000 after buying an additional 1,273,000 shares during the last quarter. 80.79% of the stock is owned by institutional investors and hedge funds.

Epizyme (NASDAQ:EPZM) opened at 9.00 on Tuesday. The firm has a 50 day moving average of $8.76 and a 200-day moving average of $10.13. Epizyme has a 52-week low of $7.02 and a 52-week high of $18.29. The stock’s market cap is $521.60 million.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.03. Epizyme had a negative net margin of 5,174.49% and a negative return on equity of 43.05%. Equities analysts anticipate that Epizyme will post ($2.20) earnings per share for the current fiscal year.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

5 Day Chart for NASDAQ:EPZM

Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.